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EVALUATION OF INDOLE-BASED PROBES FOR HIGHTHROUGHPUT SCREENING OF DRUG BINDING TO HUMAN
SERUM ALBUMIN: ANALYSIS BY HIGH-PERFORMANCE
AFFINITY CHROMATOGRAPHY
Mandi L. Conrad, Annette C. Moser, and David S. Hage*
Chemistry Department, University of Nebraska, Lincoln, NE 68588-0304 (USA)

Abstract
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There has been growing interest in the use of rapid and selective separation methods such as highperformance affinity chromatography (HPAC) or affinity capillary electrophoresis (ACE) for the
characterization of drug-protein interactions. L-Tryptophan is commonly used in these and other
methods as a site-selective probe for examining the binding of small solutes and drugs at Sudlow
site II on the protein human serum albumin (HSA). However, solutions of L-tryptophan can be
unstable and are generally prepared fresh daily for these studies. In this report, HPAC was used to
examine other indole compounds as possible replacements for L-tryptophan as a site-selective
probe for use in the high-throughput screening of drug binding to HSA; the implications of these
results in the use of such compounds in ACE were also considered. The probe candidates that
were tested included indole-3-acetic acid, indole-3-carboxylic acid, indole-3-butyric acid,
indole-3-propionic acid, indole-3-methanol, 3-acetylindole, and 3-methylindole. All of these
compounds were found by 1H NMR spectroscopy and UV/vis spectroscopy to be stable for up to
three weeks at room temperature when in pH 7.4, 0.067 M phosphate buffer. The binding of these
compounds was examined by using columns that contained immobilized HSA. 3-Acetylindole
was found to be the best candidate in this group for use as an alternative probe to L-tryptophan for
Sudlow site II. This probe had the same binding site and a similar affinity to L-tryptophan but was
more stable in aqueous solution, making it suitable for high-throughput screening of drug-HSA
binding in both HPAC and ACE.
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1 Introduction
Human serum albumin (HSA) is a soluble protein that is responsible for the binding and
transportation of many low-molecular-weight compounds in blood [1]. The interaction of
drugs with this protein is known to affect such properties as the distribution, excretion,
toxicity and activity of pharmaceutical agents [2]. Many drugs are thought to bind to a series
of relatively well-defined regions on this protein. The two regions that are most commonly
involved in these interactions are the warfarin-azapropazone site of HSA (also known as
Sudlow site I) and the indole-benzodiazepine site (Sudlow site II). Crystallographic studies
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have identified the location of these sites as being in the IIA and IIIA subdomains of HSA,
respectively [3,4].
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L-Tryptophan is an essential amino acid and a precursor of serotonin [5]. L-Tryptophan is
known to bind to Sudlow site II of HSA and is commonly used as a site-selective probe for
this region in drug binding sites [6–8]. The main disadvantage of this probe is Ltryptophan’s relatively instability in aqueous solutions, requiring that fresh samples and
solutions of this chemical be prepared on a daily basis. This instability is thought to be due,
in part, to the oxidation of tryptophan. Degradation products that have been noted when
aqueous solutions of L-tryptophan are exposed to ultraviolet light include Nformylkynurenine, kynurenine, dioxindolyalanine, aminoindolenine, cinnoline, and
quinazoline, although other products are possible in the presence of methylene blue (i.e., an
oxidizing agent) [9–11]. Although other compounds have been used as probes for Sudlow
site II (e.g., dansylsarcosine and various benzodiazepines), the well-characterized and
selective interaction that occurs between L-tryptophan and HSA has continued to make Ltryptophan popular as probe in drug binding studies despite its stability problems [6–8].
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Many techniques have been utilized to study drug interactions with HSA. These techniques
include X-ray crystallography [12,13], fluorescence spectroscopy [14], absorption
spectroscopy [14], ultrafiltration or dialysis [15–17], capillary electrophoresis [18,19],
surface plasmon resonance [20] and nuclear magnetic resonance (NMR) spectroscopy [21].
High-performance affinity chromatography (HPAC) and affinity capillary electrophoresis
(ACE) are two “non-gel” separation methods that can also be used for such studies. HPAC
can be employed in investigations of drug-HSA interactions by utilizing an HPLC support
that contains immobilized HSA as the stationary phase [22–29], with results that have been
shown to give good correlation with the behavior reported for HSA in solution [25,30–36].
ACE can make use of soluble HSA in the study of drug interactions and competition, and
has also been shown to give correlation versus reference techniques in work with HSA and
related proteins [37–42]. The relative high speed of these methods and their ability to be
used as part of automated systems have made both HPAC and ACE attractive for use in the
high-throughput screening and analysis of binding by drugs to proteins such as HSA
[22,23,37,38].
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The object of this study is to examine several indole compounds as possible alternatives to
L-tryptophan for use as site-selective probes for Sudlow site II of HSA. The compounds that
will be considered are shown in Figure 1. One item of particular interest is whether one or
more of these structural analog of L-tryptophan can be used as a selective probe for HSA
while reducing or eliminating the problems with instability that occur for L-tryptophan in an
aqueous solution. The variety of analogs that are available for L-tryptophan is an appealing
feature of working with this class of agents in such a study. The long-term stability of these
compounds in pH 7.4 phosphate buffer will be examined by 1H NMR and UV/vis
spectroscopy, as well as by HPAC using HSA columns. Frontal analysis will be used to
characterize the binding of these compounds with HSA at pH 7.4 and 37°C. Competition
studies between these compounds and L-tryptophan will be performed to see if these agents
interact with Sudlow site II. From this information, it should be possible to determine if any
of these indole-related compounds can be used as an alternative to L-tryptophan as siteselective probes when HPAC is employed for the high-throughput analysis of binding by
drugs and other chemicals to HSA. The extension of these results to work involving ACE
for drug-protein binding studies will also be considered.
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2 Materials and methods
2.1 Reagents
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The HSA (Cohn fraction V, 99% globulin and fatty acid free) and L-tryptophan (99.5%
pure) were from Sigma (St. Louis, MO, USA). The Nucleosil Si-300 (7 µm particle
diameter, 300 Å pore size) was obtained from Alltech (Deerfield, IL, USA). All aqueous
solutions were prepared using water from a Nanopure water system (Barnstead, Dubuque,
IA, USA). Indole-3-acetic acid (98%), indole-3-carboxylic acid (99%), indole-3-butyric acid
(99%), indole-3-propionic acid (99%), indole-3-methanol (98%), 3-acetylindole (98%), and
3-methylindole (98%) were obtained from Aldrich (Milwaukee, WI, USA). Deuterated
dimethylsulfoxide (DMSO-d6) (99.96% pure) was obtained from Aldrich (St. Louis, MO,
USA). Deuterium oxide (>98%) was purchased from Cambridge Isotopes (Andover, MA,
USA).
2.2 Apparatus
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The HPLC system consisted of two Jasco PU-980 pumps (Easton, MD, USA), a Dynamax
S200 pump (Woburn, MA, USA), and a Waters 509 UV/vis absorbance detector (Milford,
MA, USA). Data were collected from this system using LabView 5.1 software (National
Instruments, Austin, TX, USA). Injections were made using a Rheodyne valve (Rohnert
Park, CA, USA) equipped with a 20 µL sample loop. The column temperature was
controlled using a Fisher Scientific 9100 circulator (Pittsburgh, PA, USA) and an Alltech
water jacket. Columns were downward packed using an HPLC slurry packer from Alltech.
The pH meter used to prepare samples for the NMR studies was an IQ240 (IQ Scientific
Instruments, Carlsbad, CA, USA) equipped with an ion selective field effect transistor
(ISFET) probe. The NMR spectra were acquired on a Bruker DRX Avance 400 MHz NMR
using a QNP probe and X-WinNMR as the processing program (Bruker, Billerica, MA,
USA). These spectra were analyzed using Nuts from Acorn NMR (Livermore, CA, USA)
and XWIN PLOT from Bruker. Sixty-four scans were acquired during each 1H NMR
experiment. UV/vis spectra were acquired by using a Shimadzu UV-2401 spectrophotometer
(Kansas City, MS, USA) with matched quartz cuvettes. These spectra were obtained from
400 to 200 nm in 0.5 nm intervals.
2.3 NMR analysis and stability studies
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Deuterated phosphate buffer was prepared by adding 0.0912 g of monobasic potassium
phosphate to 10.0 mL deuterium oxide to create a 0.067 M phosphate solution. A second
0.067 M phosphate solution was made by adding 0.1167 g dibasic potassium phosphate to
10.0 mL deuterium oxide. These two solutions were mixed to create a pH 7.4 phosphate
buffer (or pD when using the deuterated buffer salts).
A saturated solution (i.e., containing roughly 200 µM) of each probe candidate was prepared
in the pH 7.4, 0.067 M deuterated phosphate buffer for use in the NMR stability studies.
These saturated solutions were prepared by adding the compounds in excess to the
deuterated buffer, followed by sonication of these solutions for several hours. The samples
were then centrifuged to remove any undissolved material and the supernatant was removed
for analysis by NMR. Immediately following the preparation of each sample, a 1H NMR
spectrum was taken. Each sample was then separated into two portions which were stored at
25°C in the dark or in the presence of normal laboratory lighting. 1H NMR spectra were
acquired for these samples over the course of 3–4 weeks. These solutions were also
examined visually throughout this period of time for any changes in color or signs of
precipitation.
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In later experiments, stability studies were also conducted to compare L-tryptophan with 3acetylindole, one of the alternative probes identified in this study. The stability of these two
compounds in a pH 7.4, 0.067 M phosphate buffer was compared was by using zonal elution
(see Section 2.5) and UV/Vis spectroscopy. This latter method was performed over the
course of several weeks by using an approximately 100 µM solution of each compound
stored at 25°C or 4°C and in the dark or in the presence of normal laboratory lighting.
2.4 Column preparation
Diol-bonded silica for preparation of the immobilized HSA column was made from
Nucleosil Si-300 silica according to a previous method [43]. The diol content of this support
was 164 (± 7) nmol/g silica, as determined through the use of an iodometric capillary
electrophoresis method [44]. HSA was immobilized onto a portion of this support using the
Schiff base method [32], resulting in a final support that contained 40 (± 2) mg HSA/g
silica. This support has been found in many previous reports to be a good model for soluble
HSA in drug binding experiments [25,30–36]. A second portion of the diol-bonded silica
was taken through the Schiff base method but with no HSA being added during the
immobilization step. This latter support was utilized to prepare a control column that could
be used to examine and correct for non-specific binding by each tested solute on the support
or chromatographic system.
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The immobilized HSA support and control support were downward slurry-packed at 3000
psi (20.7 MPa) into separate 5 cm × 2.1 mm i.d. stainless steel columns using pH 7.4, 0.067
M potassium phosphate buffer as the packing solution. These columns were stored at 4°C in
pH 7.4, 0.067 M potassium phosphate buffer when not in use. The mobile phase used with
these columns for drug binding studies was pH 7.4, 0.067 M potassium phosphate buffer.
Prior to its use, this mobile phase was filtered through a 0.2 µm cellulose acetate filter and
degassed under vacuum for 15 min.
2.5 Chromatographic binding studies
The samples for frontal analysis were all prepared in pH 7.4, 0.067 M potassium phosphate
buffer and were applied to the immobilized HSA column and control column at 0.5 mL/min
(typical back pressure, 300–400 psi). These studies were carried out at 37°C and using
analyte concentrations that ranged from 0.5 µM to 30 µM. These samples were all stored at
4°C when not in use. The elution of all compounds tested in this study was monitored at 260
nm.
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During the frontal analysis experiments, the pH 7.4 phosphate buffer was passed through the
immobilized HSA column until a stable baseline was obtained, at which point a valve was
used to switch to the application of a solution containing the same buffer plus a known
concentration of the probe candidate of interest. This probe candidate solution was applied
until a breakthrough curve was formed and a stable plateau in response was obtained, as
shown in Figure 2(a). A valve was then used to reapply only pH 7.4, 0.067 M phosphate to
the column; this step served to elute the retained probe candidate and to regenerate the
column for the next experiment. Identical experiments were performed on the control
column to measure and account for any non-specific interactions of the probe candidate with
the support or chromatographic system. The mean breakthrough time during each frontal
analysis experiment was determined using an in-house program written in LabView 5.1.
The mobile phase used in the zonal elution studies was pH 7.4, 0.067 M potassium
phosphate buffer that contained 0 to 300 µM L-tryptophan. These solutions were prepared
fresh on a daily basis. The injected samples contained 20 µM of the desired probe candidate
dissolved in the solution of L-tryptophan that was being used as the mobile phase. Replicate
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20 µL injections of each probe candidate sample were made in each mobile phase. Some
typical results are shown in Figure 2(b) (Note: no significant change in retention for these
samples was noted when using lower sample concentrations, indicating that linear elution
conditions were present for these analytes). The retention time for each injected compound
was determined from the central moment of its observed peak. The column void time was
determined by injecting a non-retained compound (i.e., sodium nitrate) onto the HSA
column or control column. The extra-column void time was determined by injecting sodium
nitrate onto the chromatographic system with no column present. Similar zonal elution
studies were used to evaluate the long-term stability of L-tryptophan and 3-acetylindole by
storing these samples at 4°C in the dark and injecting them periodically over the course of
several weeks onto the HSA column.

3 Results and discussion
3.1 Selection and stability of probe compounds
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The probe candidates shown in Figure 1 were originally chosen based on their structural
resemblance to L-tryptophan. It has been noted previously that the indole ring on Ltryptophan is a key component in the interaction of this solute with HSA [1,4]. Thus, all of
the selected probe candidates had indole rings with side groups at the 3-position, the same
position at which L-tryptophan has a substituent on its indole ring. One difference between
the selected probe candidates and L-tryptophan is that these candidates all lack a chiral
center. This was a desirable feature for the use of such probes in drug-protein binding
studies because it avoids the added complexity or expense that arises when the chiral forms
of a solute have different interactions with HSA, as occurs for D- and L-tryptophan [45].
Other more minor issues that were considered during the initial selection of these probe
candidates included their relative cost, purity, and solubility in an aqueous solution (see
Table 1).
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The main issue of concern with the use of L-tryptophan as a probe for HSA was the limited
stability of this chemical in an aqueous solution. This problem is illustrated in Figure 3(a), in
which UV/Vis spectra were acquired over the course of several days for a solution that
contained 110 µM L-tryptophan in pH 7.4, 0.067 M phosphate buffer. In this example,
storing the solution of L-tryptophan at 25°C in the presence of normal laboratory lighting
gave rise to significant changes in the UV/vis spectra within two days of this solution's
preparation (note: the same solution when stored in the dark at 4°C was found to be stable
for about 9 days). In contrast to this result, a solution in pH 7.4, 0.067 M phosphate buffer
that containing about the same concentration of 3-acetylindole (one of the probe candidates
in Figure 1) showed no significant changes in its UV/Vis spectrum under any of the tested
storage conditions, as illustrated in Figure 3(b). Similar stability to 3-acetylindole was noted
for all of the other probe candidates (data not shown). The stability of each probe candidate
was also tested by using 1H NMR spectroscopy. This second method indicated that these
candidates were stable for at least three weeks in pH 7.4, 0.067 M phosphate buffer when
stored either in the dark or in the presence of normal laboratory lighting and at either 4°C or
25°C. Thus, all of these probe candidates appeared to have greater stability than Ltryptophan under such conditions.
The effect of this change in L-tryptophan solutions during drug-binding studies was next
considered. This was examined by looking at how the apparent retention for L-tryptophan
on an HSA column changed over time after the L-tryptophan sample had been stored for
various lengths of time in pH 7.4, 0.067 M phosphate buffer at 4°C in the dark. Injections of
3-acetylindole were also made as a stable control to monitor the overall activity of the HAS
column (note: 3-acetylindole was used in this case because it was later found in this study to
be one of more promising alternative probes for Sudlow site II). A 20 µM sample of each
J Sep Sci. Author manuscript; available in PMC 2009 October 25.
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compound was injected over the course of two weeks onto the same HSA column. The
results are shown in Figure 4. It was found that the apparent peak observed for L-tryptophan
shifted by 10–11% to longer retention times and larger retention factors over the two week
period. However, only a 4% change was noted for injections of 3-acetylindole, which was
later shown to have the same binding site as L-tryptophan on HSA. These results indicated
that changes in the stability of an L-tryptophan solution could produce noticeable effects
during the use of this compound as a probe for HSA.
The relatively strong UV absorbance of the various indole probes examined in this work (as
demonstrated in Figure 3 for L-tryptophan and 3-acetylindole) should make it convenient to
monitor such agents when they are used as site-specific probes in HPAC or ACE. A strong
absorbance by the probe is desirable in these methods because it allows only a small amount
of the probe to be injected and monitored. The analyte that is being placed into the mobile
phase or running buffer during such studies may also have absorbance in the UV range;
however, this generally does not create a significant problem in HPAC or ACE if the analyte
is present at a consistent level and produces a constant background signal.
3.2 Binding of probe candidates to HSA
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All of the probe candidates were evaluated for their binding to HSA by using the method of
frontal analysis. This work involved the continuous application of solutions that contained
known concentrations of each probe candidate to the HSA column or a control column. As
the binding sites in the column became saturated, the amount of analyte that eluted from the
column gradually increased, producing a characteristic breakthrough curve, as shown Figure
2(a). The mean position of each breakthrough curve was then determined at each applied
concentration of the probe candidate and analyzed according to equations that have been
previously derived to describe various binding models [24].
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Prior to studying the binding of each probe candidate on the HSA column, the presence of
any non-specific binding to the support was also examined by conducting frontal analysis
studies with these same compounds on the control column. Figure 5 shows the results
obtained at a concentration of 5 µM for each probe candidate. Indole-3-carboxylic acid had
essentially no significant binding to the control column, while indole-3-butyric acid and
indole-3-methanol had only small retention on this column (e.g., total breakthrough times in
Figure 5, including the column and system void time, below 120 s). Probe candidates with
larger but still acceptable levels of non-specific binding included indole-3-acetic acid and 3acetylindole (total breakthrough times below 200 s in Figure 5). The final two candidates,
indole-3-proprionic acid and 3-methylindole, produced much broader breakthrough curves
and exhibited higher levels of non-specific binding (breakthrough times greater than 200 s in
Figure 5). These latter two candidates were considered for possible elimination in later
HPAC experiments because of these characteristics; however, non-specific binding by these
candidates would be expected to be less important in ACE due to the lower available surface
area for adsorption that is often present in this method versus HPAC.
Once the non-specific binding of each analyte to the control column had been measured,
these results were used to correct for non-specific binding in the frontal analysis data that
were obtained on an HSA column under the same probe concentration conditions. The
corrected data were then analyzed to determine the type and strength of binding that was
present between each remaining probe candidate and HSA. For example, a probe that has
1:1 binding with HSA (as occurs for L-tryptophan) should give a response that fits the
following equation,
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(1)

in which mLapp is the measured binding capacity of the column at a given applied
concentration of the probe candidate [A], mL is the total moles of binding sites in the column
for the probe candidate, and KA is the association equilibrium constant for this interaction
[22,24]. This equation predicts that a plot of 1/mlapp versus 1/[A] should result in a linear
relationship that can be used to provide the values of KA and mL from the slope and
intercept. If the plot is not linear, then multi-site interactions are present and alternative
equations and models can be used for data analysis to obtain the binding parameters for the
system [24,46].
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Figure 6 shows an example of a plot that was obtained when Eq. (1) was used to analyze the
results for indole-3-acetic acid (r2 = 0.9974, n = 7). The linear response that was obtained
indicated that this particular probe candidate had a single major binding site on HSA.
Similar fits to a model based on a single major binding site were obtained for indole-3carboxylic acid (r2 = 0.9998, n = 8) and 3-acetylindole (r2 = 0.9606, n = 9). The indole-3propionic acid and indole-3-butyric acid gave greater variability in their results but also gave
a reasonable fit to a one-site model (r2 = 0.8083 at n = 7 and r2 = 0.7731 at n = 5,
respectively); however, this variability plus the strong retention of these candidates on the
HSA column lead to their not being examined further in later studies.
The values of KA and mL that were obtained from these fits to a model based on one major
binding site are summarized in Table 2. Indole-3-acetic acid gave the largest association
equilibrium constant for the HSA column in the group of tested probe candidates, with a
value that was over 300-fold larger than the KA value of 1.1 × 104 M−1 that has been
previously reported for L-tryptophan with HSA [45]. Indole-3-propionic acid gave an
association equilibrium constant that was 10-fold larger than that for L-tryptophan and 3acetylindole had a KA value that was 7-fold larger. Indole-3-carboxylic acid gave a slightly
lower association equilibrium constant, with a value that was only 77% of that for Ltryptophan with HSA. These results indicated that the tested probe candidates covered a nice
range of both higher and lower association equilibrium constants for high-throughput
screening studies of drug binding to HSA. Being able to adjust the affinity of such probe
candidates would be useful in helping adjust analyte retention/migration in either HPAC or
ACE [45–49].
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A comparison was also made of the total binding capacities and specific activities that were
determined for each probe candidate versus the protein content of the HSA column. This
comparison was made by using a total protein content for the column of 4.7 (± 0.2) × 10−8
mol HSA, as calculated by using a protein content for the support of 40 mg HSA/g silica
along with a molecular weight for HSA of 66.5 kDa and a packing density for the support of
0.45 g/cm3. The resulting specific activity for each compound (given in units of mol analyte/
mol HSA) that was calculated from this information is given in Table 2. Most of probe
candidates gave specific activities that were less than or equal to one, as would be expected
for a drug or solute with a single major binding site on HSA (note: values less than one can
be obtained in HPAC if not all of the binding sites are active; when using soluble HSA in
ACE, a value near unity would be expected for a 1:1 interaction) [45,46]. The only
exception was indole-3-carboxylic acid, for which a specific activity between 2 and 3 was
obtained. This result for indole-3-carboxylic acid indicated that multi-site interactions were
present in this case, as was confirmed by the presence of some curvature at high
concentrations for plots that were prepared according to Eq. (1). This property would tend to
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make indole-3-carboxylic acid unsuitable as a site-specific probe in the use of either ACE
for high-throughput screening of drug binding to HSA.
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3.3 Competition of probe candidates with L-tryptophan
After each probe candidate had been evaluated for its overall binding to HSA, its binding to
Sudlow site II was specifically examined by looking at the competition of the probe
candidate with L-tryptophan. These competition studies were carried out on the HSA
column by using zonal elution experiments. In these experiments a small injection of the
probe candidate (A) was made in the presence of mobile phases that contained various
known concentrations of L-tryptophan (competing agent, I) while the retention of the
injected analyte was monitored. The following relationship can be used to describe the
retention that will be observed for a system in which A and I have direct competition at a
single binding site (e.g., Sudlow site II, when using L-tryptophan as the competing agent)
[24].

(2)
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In this equation, k is the observed retention factor for the analyte, VM is the column void
volume, mL represents the moles of common binding sites, KI is the association equilibrium
constant for the competing agent at the site of competition and KA is the association
equilibrium constant for the analyte at this same site. According to Eq. (2), a plot of 1/k
versus [I] should give a linear relationship if A and I have direct competition at a single site
and A has no other interactions with the column. An example of such a plot is shown in
Figure 7. If a non-linear relationship is observed, then the analyte has multiple binding sites
on the column and/or multiple sites of interaction with the competing agent [24].
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Of the various remaining probe candidates that were examined, only 3-acetylindole gave a
reasonably linear relationship when the results of its competition study were examined by
using Eq. (2) (see Figure 7). This result indicated that 3-acetylindole was competing directly
with L-tryptophan at Sudlow site II. As expected from the previous frontal analysis
experiments, indole-3-carboxylic acid gave a non-linear graph when its data were examined
according to Eq. (2), as caused by the presence of multi-site interactions of this compound
with HSA. Some nonlinear behavior was also noted for indole-3-acetic acid, which is
believed to be due to the presence of weak interactions with HSA that were not detected
under the conditions used in the frontal analysis experiments. The presence of a much
smaller amount of curvature from such interactions may also have been present for 3acetylindole, as indicated in Figure 7.

4 Conclusions
Various indole-related compounds were examined as alternatives to L-tryptophan for use as
site-selective probes in drug-protein binding studies involving HSA. All of the tested probe
candidates had greater stability than L-tryptophan in aqueous solution but many of these
suffered from other limitations when used in binding studies. For example, indole-3propionic acid and 3-methylindole had a relatively large amount of non-specific binding to
the support, which could limit their usefulness in HPAC but probably not ACE. Indole-3carboxylic acid had significant multi-site interactions with HSA, which would make it
unsuitable as a site-selective probe for either HPAC or ACE studies. The only candidate in
the group of tested compounds that gave reasonably strong binding to HSA, acceptable
levels of non-specific binding, and good competition with L-tryptophan was 3-acetylindole.
This compound had a comparable affinity to L-tryptophan for HSA and yet was much more
J Sep Sci. Author manuscript; available in PMC 2009 October 25.
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stable in an aqueous solution. These properties should make 3-acetylindole useful as a
possible alternative to L-tryptophan for future work in the high-throughput screening of drug
interactions with the Sudlow site II of HSA by either HPAC or ACE.

Abbreviations
ACE

Affinity capillary electrophoresis

HPAC

high-performance affinity chromatography

HSA

human serum albumin

NMR

nuclear magnetic resonance
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Figure 1.

Structures of several probe candidates for Sudlow site II of HSA. The asterisk shows the
location of the chiral center in tryptophan.
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Figure 2.

(a) Typical breakthrough curves seen during the frontal analysis studies that were performed
for this report and (b) typical results obtained during the zonal elution studies examining the
competition of a probe candidate with L-tryptophan. The concentrations that are shown by
these curves represent (a) the applied concentration of 3-acetylindole or (b) the
concentrations of L-tryptophan in the mobile phase. All other conditions are given in the
text.
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Figure 3.

UV/vis spectra for solutions of (a) L-tryptophan and (b) 3-acetylindole in pH 7.4, 0.067 M
phosphate buffer and stored at 25°C in the presence of normal laboratory lighting.
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Figure 4.

Shift in observed retention for repeated injections of a sample of (a) L-tryptophan or (b) 3acetylindole onto an HSA column after these samples had been stored for various lengths of
time at 4°C in the dark. The dashed vertical lines are shown for reference and indicate the
location for the peak maximum for each injected compound at the beginning of the stability
study.
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Figure 5.
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Non-specific binding by each of the probe candidates on the control column at an applied
concentration of 5 µM. For the sake of comparison, the response on the y-axis has been
normalized for each probe candidate to correct for differences in their molar absorptivities at
the detection wavelength and to give them breakthrough curves with equivalent plateau
values.

J Sep Sci. Author manuscript; available in PMC 2009 October 25.

Conrad et al.

Page 16

NIH-PA Author Manuscript
NIH-PA Author Manuscript

Figure 6.

Frontal analysis results for indole-3-acetic acid, as analyzed according to Eq. (1). The bestfit line for this plot was y = 0.76 (± 0.02) x + 0.135 (± 0.002), with r2 = 0.9974 (n = 7). The
error bars represent a range of ± 1 S.D. for each point. The inset shows the results obtained
when the same frontal analysis data were analyzed according to a non-reciprocal plot.
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Figure 7.

Results of competition studies for injections of 3-acetylindole in the presence of various
concentrations of L-tryptophan. The error bars represent a range of ± 1 S.D. for each point.
These results were analyzed according to Eq. (2), giving a best fit line over the lower six
points in this plot (see dashed line) of y = 1370 (± 70) x + 0.052 (± 0.009), with r2 = 0.9872.
A slightly lower slope but comparable intercept was obtained when using the entire set of
points in this plot (see solid line).
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Purity, cost and solubility of selected probe candidates for Sudlow site IIa
Compound

Cost/g ($)

Available Purity

Solubility (mg/L)

Indole-3-acetic acid

3.32

98%

≤ 1500

Indole-3-carboxylic acid

22.60

99%

≤ 1610

3-Acetylindole

18.90

98%

≤ 1590

3-Methylindole

3.22

98%

≤ 1320

Indole-3-butyric acid

5.36

99%

≤ 250

Indole-3-propionic acid

11.66

99%

≤ 3940

Indole-3-methanol

10.60

98%

≤ 8340

L-Tryptophan

10.20

98.5%

≤ 2040

a

The costs and purities provided are based on data obtained from commercial suppliers in 2007. The solubilities listed are based on the Merck
index.
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Association equilibrium constants (KA), total binding capacity (mL) and specific activity for the probe
candidate with HSA
Probe Candidate

Association Equilibrium
Constant, KA (M−1)

Total Binding
Capacity, mL (mol)

Specific Activity
(mol/mol HSA)

Indole-3-acetic acida

3.4 (± 0.08) × 106

3.7 (± 0.05) × 10−8

0.78 (± 0.03)

Indole-3-carboxylic acida

8.5 (± 0.2) × 103

12 (± 0.02) × 10−8

2.6 (± 0.1)

3-Acetylindole

7.8 (± 0.6) × 104

0.84 (± 0.01) × 10−8

0.18 (± 0.01)

105

10−8

0.94 (± 0.04)

2.9 (± 0.9) ×

10−8

0.62 (± 0.19)

2.6 (± 0.2) ×

10−8

0.55 (± 0.04)

Indole-3-propionic acid
3-Methylindole
Indole-3-butyric acid
Indole-3-methanol

1.1 (± 0.02) ×
5.3 (± 0.5) ×

104

9.7 (± 3.0) ×

105

1.2 (± 0.5) ×

105

4.5 (± 0.01) ×

0.12 (±0.05) ×

10−8

0.03 (± 0.01)

a

The results in this table were all obtained using a model based on a single major binding site. However, other data obtained in this report suggests
that indole-3-acetic acid and indole-3-carboxylic acid may actually have significant multi-site binding with HSA, as discussed in the text.
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